Results 201 to 210 of about 9,892 (240)

Beyond dyspnoea as an endpoint in acute heart failure trials [PDF]

, 2017
Gheorghiade, Mihai, Ruschitzka, Frank
core  

Acute Autonomic Sensory Neuropathy Causing Severe Hyponatremia: A Rare Cause of Syndrome of Inappropriate Antidiuresis. [PDF]

JCEM Case Rep
Ogawa T, Kosugi R, Hori A, Kotani M, Inoue T, Ariyasu H.   +5 more
europepmc   +1 more source

Hypertension Resistant to RAAS Inhibitors as a Prognostic Indicator for Rapid Progression to ESRD in ADPKD: A Ten-Year Follow-Up. [PDF]

Diagnostics (Basel)
Angioi A, Piras D, Lepori N, Floris M, Cabiddu G, Pani A.   +5 more
europepmc   +1 more source

Advanced small cell lung cancer with severe hyponatremia: a case report and literature review. [PDF]

Front Oncol
Li X, Xu T, Jian X.
europepmc   +1 more source

Brachial-ankle pulse wave velocity predicts liver volume in patients with autosomal dominant polycystic kidney disease. [PDF]

PLoS One
Tato W, Suwabe T, Ubara Y, Oba Y, Mizuno H, Ikuma D, Yamanouchi M, Inoue N, Sekine A, Tanaka K, Hasegawa E, Wada T, Sawa N.   +12 more
europepmc   +1 more source

GLPG2737, a CFTR Inhibitor, Prevents Cyst Growth in Preclinical Models of Autosomal Dominant Polycystic Kidney Disease.

Am J Nephrol
Dumont V, Meurisse S, Verdonck K, Salgues V, Robert T, Anquetil F, Delachaume C, Blanqué R, Liekens D, Huang Y, Hu J, Harris PC, Nakhlé J, Conrath K, Vandeghinste N, Christophe T, Comas D.   +16 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tolvaptan

Nature Reviews Drug Discovery, 2009
In May 2009, tolvaptan (Samsca; Otsuka), a selective vasopressin V(2) receptor antagonist, was approved by the US FDA for the treatment of clinically significant hypervolaemic and euvolaemic hyponatraemia.
Jalal K, Ghali, Bashar, Hamad, Uma, Yasothan, Peter, Kirkpatrick   +3 more
openaire   +3 more sources

Tolvaptan

Drugs, 2010
Tolvaptan is an orally administered, nonpeptide, selective arginine vasopressin V(2) receptor antagonist that increases free water clearance, thereby correcting low serum sodium levels. SALT-1 and -2, two identical, randomized, double-blind, placebo-controlled, multicentre trials, included patients with hypervolaemic or euvolaemic hyponatraemia (serum ...
openaire   +2 more sources

Tolvaptan

Reactions Weekly, 2017
  +10 more sources

Tolvaptan

Reactions Weekly, 2022
  +5 more sources